The University of Chicago Header Logo

Connection

Jasmin Tiro to Uterine Cervical Neoplasms

Back to Details
This is a "connection" page, showing publications Jasmin Tiro has written about Uterine Cervical Neoplasms.
Jasmin Tiro
Connection Strength
9.770
Uterine Cervical Neoplasms
  1. Process Mapping to Compare and Improve Management of Abnormal Cervical Cancer Screening Results in Two US Healthcare Systems within the PROSPR Consortium. Cancer Epidemiol Biomarkers Prev. 2025 Nov 03; 34(11):1989-1999.
    View in: PubMed
    Score: 0.737
  2. Barriers to the Equitable Implementation of Risk-Based Cervical Cancer Management Guidelines. J Gen Intern Med. 2026 Feb; 41(3):759-766.
    View in: PubMed
    Score: 0.716
  3. Delivering Guideline-Concordant Care for Patients With High-Risk HPV and Normal Cytologic Findings. JAMA Netw Open. 2025 01 02; 8(1):e2454969.
    View in: PubMed
    Score: 0.696
  4. The impact of intimate partner violence on breast and cervical cancer survivors in an integrated, safety-net setting. J Cancer Surviv. 2020 12; 14(6):906-914.
    View in: PubMed
    Score: 0.510
  5. Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. J Natl Cancer Inst. 2020 03 01; 112(3):238-246.
    View in: PubMed
    Score: 0.497
  6. Understanding Patients' Perspectives and Information Needs Following a Positive Home Human Papillomavirus Self-Sampling Kit Result. J Womens Health (Larchmt). 2019 03; 28(3):384-392.
    View in: PubMed
    Score: 0.456
  7. Cervical Cancer Burden and Opportunities for Prevention in a Safety-Net Healthcare System. Cancer Epidemiol Biomarkers Prev. 2018 12; 27(12):1398-1406.
    View in: PubMed
    Score: 0.449
  8. Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system. AIDS. 2018 08 24; 32(13):1861-1870.
    View in: PubMed
    Score: 0.448
  9. Characterizing safety-net providers' HPV vaccine recommendations to undecided parents: A pilot study. Patient Educ Couns. 2016 09; 99(9):1452-60.
    View in: PubMed
    Score: 0.385
  10. Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine. 2011 Jun 06; 29(25):4238-43.
    View in: PubMed
    Score: 0.268
  11. Human papillomavirus and cervical cancer behavioral surveillance in the US. Cancer. 2008 Nov 15; 113(10 Suppl):3013-30.
    View in: PubMed
    Score: 0.227
  12. What do women in the U.S. know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev. 2007 Feb; 16(2):288-94.
    View in: PubMed
    Score: 0.201
  13. Gaps in care across the cancer screening continuum for cervical, colorectal, and lung cancers. J Natl Cancer Inst. 2025 Dec 01; 117(12):2556-2570.
    View in: PubMed
    Score: 0.185
  14. Guideline-Concordant Surveillance After Treatment for High-Grade Cervical Dysplasia. Obstet Gynecol. 2025 May 01; 145(5):461-468.
    View in: PubMed
    Score: 0.176
  15. Cervical cancer screening rates in females living with HIV at three healthcare settings in the United States, 2010-2019. Cancer Causes Control. 2025 Mar; 36(3):275-284.
    View in: PubMed
    Score: 0.172
  16. Association Between Clinician Confidence and Making Guideline-Recommended Decisions in the Management of Abnormal Cervical Cancer Screening Results. J Gen Intern Med. 2024 Dec; 39(16):3217-3224.
    View in: PubMed
    Score: 0.169
  17. Assessing Management of Abnormal Cervical Cancer Screening Results and Concordance with Guideline Recommendations in Three US Healthcare Settings. Cancer Epidemiol Biomarkers Prev. 2024 Jul 01; 33(7):912-922.
    View in: PubMed
    Score: 0.168
  18. Characteristics of Clinicians Caring for Transgender Men and Nonbinary Individuals and Guideline Concordance of Clinicians' Cervical Cancer Screening Counseling for Cisgender Individuals Versus Transgender Men and Nonbinary Individuals with a Cervix. LGBT Health. 2024 Oct; 11(7):563-569.
    View in: PubMed
    Score: 0.166
  19. Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial. JAMA. 2023 11 28; 330(20):1971-1981.
    View in: PubMed
    Score: 0.161
  20. Disparities in Gynecologic Cancers. Cancer J. 2023 Nov-Dec 01; 29(6):343-353.
    View in: PubMed
    Score: 0.160
  21. Timing of Colposcopy and Risk of Cervical Cancer. Obstet Gynecol. 2023 11 01; 142(5):1125-1134.
    View in: PubMed
    Score: 0.158
  22. Racial and Ethnic Disparities in Cervical Cancer Screening From Three U.S. Healthcare Settings. Am J Prev Med. 2023 10; 65(4):667-677.
    View in: PubMed
    Score: 0.155
  23. Economic Evaluation of Mailed Home-Based Human Papillomavirus Self-sampling Kits for Cervical Cancer Screening. JAMA Netw Open. 2023 03 01; 6(3):e234052.
    View in: PubMed
    Score: 0.153
  24. Provider beliefs in effectiveness and recommendations for primary HPV testing in 3 health-care systems. JNCI Cancer Spectr. 2023 01 03; 7(1).
    View in: PubMed
    Score: 0.151
  25. Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022 11 01; 5(11):e2244343.
    View in: PubMed
    Score: 0.150
  26. Factors associated with timely colposcopy following an abnormal cervical cancer test result. Prev Med. 2022 11; 164:107307.
    View in: PubMed
    Score: 0.149
  27. Design of a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake in a U.S. healthcare system: The STEP trial. Contemp Clin Trials. 2022 11; 122:106960.
    View in: PubMed
    Score: 0.149
  28. Gaps in the screening process for women diagnosed with cervical cancer in four diverse US health care settings. Cancer Med. 2023 02; 12(3):3705-3717.
    View in: PubMed
    Score: 0.148
  29. Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2022 01; 154:106871.
    View in: PubMed
    Score: 0.140
  30. De-implementation of cervical cancer screening before age 21. Prev Med. 2021 12; 153:106815.
    View in: PubMed
    Score: 0.139
  31. T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates. Front Immunol. 2021; 12:624230.
    View in: PubMed
    Score: 0.134
  32. Out of reach? Correlates of cervical cancer underscreening in women with varying levels of healthcare interactions in a United States integrated delivery system. Prev Med. 2021 04; 145:106410.
    View in: PubMed
    Score: 0.132
  33. Authors' response: Cost-effectiveness evidence for HPV self-sampling could be improved by giving greater attention to vulnerable populations. Prev Med. 2020 10; 139:106081.
    View in: PubMed
    Score: 0.125
  34. Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits. J Med Screen. 2020 09; 27(3):146-156.
    View in: PubMed
    Score: 0.122
  35. Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial. JAMA Netw Open. 2019 11 01; 2(11):e1914729.
    View in: PubMed
    Score: 0.122
  36. Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort. Int J Cancer. 2019 03 15; 144(6):1460-1473.
    View in: PubMed
    Score: 0.114
  37. Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. J Gen Intern Med. 2016 Apr; 31(4):372-9.
    View in: PubMed
    Score: 0.095
  38. Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst. 2015 Jun; 107(6):djv120.
    View in: PubMed
    Score: 0.089
  39. Effects of socioeconomic status and health care access on low levels of human papillomavirus vaccination among Spanish-speaking Hispanics in California. Am J Public Health. 2013 Feb; 103(2):270-2.
    View in: PubMed
    Score: 0.075
  40. Evaluating associations between sources of information, knowledge of the human papillomavirus, and human papillomavirus vaccine uptake for adult women in California. Vaccine. 2012 Apr 19; 30(19):3003-8.
    View in: PubMed
    Score: 0.071
  41. Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics. Vaccine. 2012 Mar 16; 30(13):2368-75.
    View in: PubMed
    Score: 0.070
  42. One in four California adolescent girls have had human papillomavirus vaccination. Policy Brief UCLA Cent Health Policy Res. 2009 Feb; (PB2009-3):1-6.
    View in: PubMed
    Score: 0.058
  43. Anal Cancer and Anal Cancer Screening Knowledge, Attitudes, and Perceived Risk Among Women Living With HIV. J Low Genit Tract Dis. 2021 Jan 01; 25(1):43-47.
    View in: PubMed
    Score: 0.033
  44. Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. Cancer. 2021 03 15; 127(6):850-864.
    View in: PubMed
    Score: 0.033
  45. Cost-effectiveness studies of HPV self-sampling: A systematic review. Prev Med. 2020 03; 132:105953.
    View in: PubMed
    Score: 0.031
  46. Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials. 2018 01; 64:77-87.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.